Skip to main content
PAS 2025 Meeting Main banner
Final Program


Schedule at a Glance
Icon Legend
Back
ViewAttendees 3

Nephrology

Nephrology 1

Long-term Efficacy and Safety of Lumasiran in Patients with Primary Hyperoxaluria Type 1 in a Final Analysis of the ILLUMINATE-A Trial

Friday, April 25, 2025
4:15pm – 4:30pm HST
Location:  Convention Center: 316 A
Jeffrey M. Saland, Icahn School of Medicine at Mount Sinai, New York, NY, United States; John C.. Lieske, Mayo Clinic, Rochester, MN, United States; Richard Willey, Alnylam Pharmaceuticals, High Bridge, NJ, United States; Yaacov Frishberg, Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel; Martin Coenen, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany; Julien Hogan, Robert Debré Hospital, APHP, Paris, Ile-de-France, France; Cristin Kaspar, Alnylam Pharmaceuticals, Cambridge, MA, United States; Sally-Anne Hulton, Birmingham Womens and Childrens Hospital NHS Trust, Birmingham, England, United Kingdom

    Presenting Author(s)

  • JS

    Jeffrey M. Saland, MD, MS (he/him/his)

    Professor, Pediatric Nephrology and Hypertension
    Icahn School of Medicine at Mount Sinai
    New York, New York, United States

Disclosure(s):
Jeffrey M. Saland, MD, MS: Alnylam Pharmaceuticals (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Speaker Honorarium including speakers bureau, symposia, and expert witness)